Last reviewed 2026-04-23 · How we verify

tumor-pulsed dendritic cells

Tumor-pulsed dendritic cells stimulate an immune response against cancer cells.

Tumor-pulsed dendritic cells stimulate an immune response against cancer cells. Used for Treatment of various cancers.

At a glance

Mechanism of action

This is achieved by loading dendritic cells with tumor antigens, which are then presented to T-cells, triggering an immune response against cancer cells. This process can lead to the destruction of cancer cells and potentially induce long-term immune memory.

Approved indications

• Treatment of various cancers

Common side effects

• Fever
• Fatigue
• Headache

Key clinical trials

• Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (PHASE2)
• A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer (NA)
• Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (PHASE2)
• HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (PHASE1)
• Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer (PHASE1)
• A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) (PHASE1)
• Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies (PHASE2)
• Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.